Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.

ABSTRACT: The recent development of monoclonal antibodies (mAbs) has revolutionized the treatment armamentarium for multiple myeloma. The success of daratumumab and elotuzumab in relapsed/refractory patients, has generated tremendous enthusiasm for mAbs in this disease. Combination treatment with other anti-myeloma treatment modalities and clinical evaluation in newly diagnosed patients are expected to fundamentally change the natural history of the disease. Advances in biopharmaceutical engineering together with a robust interest in novel mAb-derivatives, including antibody drug conjugates and poly-specific antibodies are the next rapidly approaching treatment frontier in multiple myeloma. In this review, we comprehensively outline the currently available evidence and the future landscape of mAbs a

SUBMITTER: Wudhikarn K 

PROVIDER: S-EPMC7060936 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature